chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Starting the night of the vaccine I had uncontrollable shakes, nausea and stomach pains, headache, achey body, and very weak (struggled opening a water bottle.) Where i received the shot my arm is very sore from my elbow to my shoulder.
Headache, incoherent speech, dizziness, fever of 100 degrees, body aches, unsteady on feet (requiring cane). Just feeling misterable for the past 5 days
BODY PAIN; FEVER; This spontaneous report received from a patient via a company representative from concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. Per procedure, no follow-up will be requested for this case. No concomitant medications were reported.  On an unspecified date, the subject experienced body pain, and fever. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the body pain and fever was not reported. This report was non-serious.
I tested on Monday 7/25, initially negative then tested positive on Tuesday. I had a tele health visit with a nurse practitioner on Tuesday and they prescribed Paxlovid. I started taking that on 7/27. I retested on 8/1 and it was still positive. On 8/4 I was feeling better and retested on 8/5 and tested negative. I was feeling pretty good. Then I woke up on 8/6 with a sore throat, cough, and congestion and tested positive again that day. My initial symptoms had been sore throat, headache, chills, fever, and a slight cough, and a lot of diarrhea through out but I had felt completely better by 8/5. But the next day the symptoms were back and I am still feeling all of them. I will probably speak with my doctor's office again tomorrow.
Full body rash with hives that covers trunk, scalp, limbs, face, chest tightness and breathing issues.  I have had a steroid shot on 2/18/2021 and was started on a Medrol dose pack, no relief and the rash got worse. I contacted my doctor/dermatologist over the weekend and was prescribed Prenisone 60 mg. I have been taking Prednisone 60 mg daily since Sunday 2/21/2021, with Zyrtec tid, Pepcid tid and Benadryl twice daily. I have been using my bronchodilator (Albuterol) about 3-4 times daily with my daily Brillinta (diskus inhaler) to prevent airway issues. I have had no relief. My rash and hives are not fully suppressed and I they move over my body. They burn, and get hot. Ice helps but doesn't seem to make them go away.
pt recvd vax;started scratching ankles 15dec pm & lips started swelling,turned bluish;red spots on stomach;started fever 101; lasted till am 16dec;apap given;denies shortness of breath;denies any ATB,detergent or food change;
Pt stated that he started with a HA about 2 hours after receiving the vaccine and then had a fever of 101.8 for 1 day. HA continued on the second day with some abnormal breathing.  Patient reported after all symptoms were resolved.
Participant received the FLU shot and about 45 min after administration she advised of teeth pain that subsided and pressure in chest.
Allergic reaction to COVID-19 mRNA vaccine. Medium severity reaction - RASH, Pruritis.
Patient reported headache and flu-like symptoms following vaccination. The next day patient experienced redness of the skin (inflammation) increased sinus pressure and pain in the legs (body pain).
we had two of the Pfizer vaccines. After she passed away; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team.  A 60-year-old female patient received BNT162b2 (BNT162B2), as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose 1), for COVID-19 Immunization. The following information was reported: DEATH (death, medically significant) with onset 2022, outcome "fatal", described as "we had two of the Pfizer vaccines. After she passed away". The patient date of death was 2022. The reported cause of death was unknown. It was not reported if an autopsy was performed. Clinical course: The reporter stated patient had two of the Pfizer vaccines. Patient was passed away in last summer (2022).  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Reported Cause(s) of Death: we had two of the Pfizer vaccines. After she passed away
Information has been received from a physician concerning an approximately 2-month-old female who on 17-SEP-2006 was vaccinated by mouth with a 2.0 ml dose of rotavirus G1 G2 G3 G4 P1 reassortant vaccine live (human-bovine).  The physician reported that on 17-SEP-2006, the patient developed fever, vomiting and dehydration.  Unspecified medical attention was sought and the patient was subsequently hospitalized for two night.  A "rotavirus test" was performed (results not provided).  At the time of this report, the patient was recovering from the fever, vomiting and dehydration as she was noted to be "doing better". Additional information has been received from agency through the agency concerning a 10-week-old female with gastroesophageal reflux disease (GERD), kidney reflux and a spastic colon who on 15-SEP-2006, at 1415, was vaccinated by mouth with a dose of rotavirus G1 G2 G3 G4 P1 reassortant vaccine live (human-bovine).  Concomitant vaccinations on that same date included a dose in the left leg of diphtheria toxoid (+) Pertussis acellular vaccine (unspecified) (+) tetanus toxoid, a dose in the left leg of hepatitis B virus vaccine rHBsAg (yeast) (manufacturer unknown), a dose in the right leg of Hib conj vaccine (manufacturer unknown) and a dose of poliovirus vaccine live oral.  Illness at the time of vaccination included a kidney infection due to kidney reflux and e-coli bacteria.  Other concomitant therapy included famotidine.  On 17-SEP-2006, 48 hours after vaccination, the patient experienced low grade fever, diarrhea, vomiting and dehydration.  Unspecified medical attention was sought.  On 26-SEP-2006, at 1100, the patient was lethargic, had excessive sleeping and loss of appetite.  The patient was subsequently hospitalized.  The patient had a positive rotavirus stool test and other laboratory tests (not further specified) revealed dehydration with acidosis.  At the time of this report, the outcome of the diarrhea, lethargy, excessive sleeping, loss of appetite, positive rotavirus stool test and acidosis was unknown.  Additional information has been requested.
Child recieved Varicella vaccine and came down with severe case of Chicken Pox all over her body. There is a possibility she may have been exposed just before she got the vaccine.
Initially experienced high fever, muscle, and joint pain from head to knee on the side of the body that was vaccinated. Later developed hard, warm bump around injection site which has mostly subsided. 4 days after the shot I started experiencing intense headaches and dizziness, plus sensitivity to light.
I had soreness in my arm after receiving the vaccine for about two days. I noticed symptoms of heart palpitations in early February. I was monitoring my blood pressure to see if we needed to lower or increase my medication and that was when we noticed the heart palpitations. I have been referred to a cardiologist.
Jaw numbness and tightness, dizziness. Patient vital signs assessed and found within normal limits. Upon further monitoring, patient reports symptoms subsided. Vital signs: 10:30am BP: 136/81, HR 110 bpm, O2 sat 98.8%, RR 12, Temperature 97.1 F, Lung sounds clear. 10:45am: BP 133/89, HR 78 bpm, O2 sat 98%, RR 12, Temperature 97.2 F, Lung sounds clear.  11:00am: BP 131/80, HR 81bpm, O2 sat 97%, RR 12, Temperature 97.1 F, lung sounds clear.
Roughly one week before the vaccine, I received an iron infusion without experiencing any adverse event. One week after I was vaccinated, I received my 2nd infusion. After the infusion, I developed itchy and raised rash on torso and leg. One day after, I developed vasculitic rash (red, patchy, not itchy) on both legs.  The rash slowly went away.  In communication with my hematologist, given my experience with the first infusion, the probability is very low for me to experience what I had had it not been for the vaccine, which potentially altered my immune response.
Pt recvd 2 doses of Hep B vax & subseqently tested pos for Hep A, B & C p/2nd dose; pt was hospitalized; Reporter has no addtl info;
1. swollen, red area on the left arm around 3 inches below the injection site. lasted 3 days 2. bruising at the inside corner of the left eye and the eye was bloodshot. vision was not impacted. lasted 3 to 4 days. *both began around 12 hours post vaccination *patient did not seek any medication attention for these effects. reported to the pharmacy on 7/30/23 (6 days following the vaccine). reports everything has resolved now.
Fever between 99 and 101 on second day. No fever on subsequent days.  Swollen upper arm, red rash, pain in arm for the next 5 days. 6th day the swelling and pain dissipated.  Still have the rash and some itching.
Varicella - Information has been received from a healthcare professional concerning 3 students ranging in ages from kindergarten to third grade who at unknown dates were vaccinated with a dose  of varicella virus vaccine live site unknown.  The reporter stated that in April 2000 a total of 7 students from one school.  Including those that were vaccinated, had developed chicken pox.  An undertemined number student sought unspecified medical attention.  Also reprorted were 15 students from another school who were vacinated and experienced similiar events (waes 00041090).
congestive heart failure; Heart problem/heart down; This is a spontaneous report from a Pfizer-sponsored program.  A contactable consumer reported that a 90-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as dose 1, single and via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as dose 2, single for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. On an unspecified date, the patient experienced congestive heart failure and heart problem/heart down. The patient had a heart problem after the Pfizer Covid vaccine. The patient had congestive heart failure and was 90 years old. The hospital said for the patient to get the second shot and it shut her heart down and the patient passed away. The patient died on an unspecified date. It was not reported if an autopsy was performed.  Information on Lot/Batch number has been requested.; Reported Cause(s) of Death: congestive heart failure; Heart problem/heart down
This case was reported by a pharmacist and described the occurrence of headache in a female subject of unspecified age who was vaccinated with FLUARIX, GlaxoSmithKline.  On an unspecified date the subject received unspecified dose of FLUARIX (unknown).  At an unspecified time after vaccination with FLUARIX, the subject experienced headache.  The subject was treated with sumatriptan succinate (Imitrex).  At the time of reporting the outcome of the event was unspecified.
Approximately 6 hours (3pm) after receiving the first dose of the pediatric Moderna vaccine, the patient woke up at daycare with large hives on the right side of her face on her cheek and nose. The patient also had hives on her arms, legs, and back.  The patient's pediatrician was contacted for guidance and they recommended 4ml of Benadryl every 8 hours. Upon speaking to the pediatrician, the hives had mostly resolved with one small hive remaining on the patients back and a red spot on the patient's cheek and left arm so Benadryl was not given at that time.  At approximately 7pm, the patient did have a recurrence of the hives on her back and a new hive under her left eye. At that time the patient was given a dose of Benadryl and hives completely resolved by 9pm.  The patient did not display any respiratory issues or itching with the hives and swelling was present on the patient's face around the hives but did not extend to the eyes or mouth
Excessive multicolor bruising about 3 inches across  at the injection site; This is a spontaneous case, reported by pharmacist to Agency (reference number: SEQ19-03773) and initially received on 02-Oct-2019,  concernig a 62-year-old female patient.   The patient's relevant medical history included: type 2 diabetes, hypertension and concomitant medications included: Lisinopril, metformin, Aleve (for back ache).  On 25-Sep-2019, the patient was administered Flucelvax QIV [Influenza vaccine, subunit influenza virus vaccine polyvalent, dose: 0.5ml , route of administration: intramuscular, anatomical location: deltoid right, batch number: 261204, expiration date: 26-Jun-2020] for influenza prophylaxis.  On the same day, several hours after vaccination, the patient developed injection site bruising.   On 02-Oct-2019 the pharmacist reported that the patient had excessive bruising at site that is healing. Multicolour bruising probably about 3 inches across. Could see spot of administration and it was in the correct location.  On 09-Sep-2019, 2 weeks after vaccine administration, the outcome of the event was resolved.  The reporter assessed the case as non-serious and did not provide causality assessment to Flucelvax QIV.  Follow up received from a pharmacist on 18-Oct-2019: Event expectedness, event start, stop date and outcome updated. The narrative was amended accordingly.  Company comment: The patient experienced injection site bruising after vaccination with the suspect product Flucelvax QIV. Chronology is plausible. Medical history of type 2 diabetes may have contributed to development of the event. Considering all the above mentioned, causal role of the suspect product is assessed as related.; Sender's Comments: Excessive multicolor bruising about 3 inches across  at the injection site considered as related to the Flucelvax.
I'm not sure if it is because of vaccine, but three months later (in July) I was having nausea, abdominal pain and overall feeling of unwell. I went to my doctor on 7/20/21  and was tested the following week and learned I had the stomach infection: h pylori disease
SICK for three days  in bed ,i have a round red spot were shot was given and some of it  scabs up it's like this all the time
Leg paralysis 12 hours after.; Slower cognitive functions for 5 days.; Leg numbing for 5 days.; Brain fog and fatigue for 5 days; Brain fog and fatigue for 5 days.; This is a spontaneous report from a contactable consumer. A 36-year-old male patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Lot Number: EN6204), via an unspecified route of administration, at the age of 36 years, administered on the left arm on 05Apr2021 12:00 at a SINGLE DOSE for covid-19 immunisation. The patient's medical history was not reported. There were no concomitant medications. On 05Apr2021 23:00, the patient experienced leg paralysis 12 hours after, leg numbing for 5 days, brain fog and fatigue for 5 days and slower cognitive functions for 5 days. No treatment was received for the events. The outcome of the events was not recovered.
400p gave injection. 430 patient came back with itching of the face and neck. BENADRYL 50mg po given. 505 neck swelling noted. No difficulty breathing. C/o scratchy throat. 520 911 called. 525 coughing, EPI PEN. Transferred at 545.
after I got my 2nd vaccine I was diagnosed with blood clot; This is a spontaneous report from a contactable consumer (patient).  A 74-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Batch/Lot Number: EW0173; Expiration Date: 31Aug2021), via intramuscular route of administration, administered in Arm Left on 20May2021 13:00 (at the age of 74-year-old) as 2nd dose, single dose for COVID-19 immunisation. Medical history included Blood pressure from an unknown date and unknown if ongoing. Concomitant medication included nebivolol hydrochloride (BYSTOLIC) taken for blood pressure, start and stop date were not reported. The patient previously received first dose of BNT162B2 (Lot number: EW0172; 74-year age at time vaccination) intramuscular, administered in Arm Left on 29Apr2021 (approximately 1pm afternoon) for COVID-19 immunisation. Patient stated, I do not know if it was related to the vaccine, but I thought it was interesting that 2 weeks to the day after I got my 2nd vaccine I was diagnosed with blood clot (28May2021), and I never had a blood clot I am on blood thinners now, I just said that was interesting I don't know where it came from I had no injury, I am very active. there was no reason for me to have the blood clot other than I do get the vaccine 2 weeks prior to the diagnoses. Again stated, I got the vaccine on 20May, I started noticing it on 28May. Patient stated, I did not go to the hospital to get diagnosed I had ultrasound. Patient stated diagnosis date of blood clot was 03Jun2021 and Eliquis (each pill is 5 milligrams and I have to take 4pills a day) used for blood thinner. The patient underwent lab tests and procedures which included ultrasound: blood clot on 03Jun2021.Therapeutic measures were taken as a result of after patient got my 2nd vaccine i was diagnosed with blood clot. The outcome of event was unknown.
Occasional Urinary tract infection; Hair thinning; Plaque Psoriasis flare-up /flare up of Rare break out on shins/ankles and scaring on legs; Occasional Sinus infection; Flu-like symptoms; This spontaneous case was reported by a consumer and describes the occurrence of URINARY TRACT INFECTION (Occasional Urinary tract infection), ALOPECIA (Hair thinning), INFLUENZA LIKE ILLNESS (Flu-like symptoms), PSORIASIS (Plaque Psoriasis flare-up /flare up of Rare break out on shins/ankles and scaring on legs) and SINUSITIS (Occasional Sinus infection) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product RISANKIZUMAB RZAA (SKYRIZI [RISANKIZUMAB RZAA]) for Psoriasis.    Concomitant products included COVID-19 VACCINE NRVV AD26 (JNJ 78436735) (JANSSEN COVID-19 VACCINE) for COVID-19 vaccination.   On 20-Jan-2022, the patient started RISANKIZUMAB RZAA (SKYRIZI [RISANKIZUMAB RZAA]) (Subcutaneous) at an unspecified dose. On 01-Jun-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In 2022, the patient experienced INFLUENZA LIKE ILLNESS (Flu-like symptoms). On an unknown date, the patient experienced URINARY TRACT INFECTION (Occasional Urinary tract infection), ALOPECIA (Hair thinning), PSORIASIS (Plaque Psoriasis flare-up /flare up of Rare break out on shins/ankles and scaring on legs) and SINUSITIS (Occasional Sinus infection). At the time of the report, URINARY TRACT INFECTION (Occasional Urinary tract infection), INFLUENZA LIKE ILLNESS (Flu-like symptoms) and SINUSITIS (Occasional Sinus infection) outcome was unknown and ALOPECIA (Hair thinning) and PSORIASIS (Plaque Psoriasis flare-up /flare up of Rare break out on shins/ankles and scaring on legs) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       It was unknown if patient was enrolled in a COVID-19 Vaccine Trial. The reporter's causality for all event(s) with Skyrizi was no reasonable possibility. Treatment information was not reported.
This spontaneous report as received from a pharmacist refers to a patient of unknown age and gender. No concurrent condition, medical history or allergy/drug reactions were reported. On 23-OCT-2015 18:29, the patient was vaccinated with improperly stored RECOMBIVAX HB with lot number: L016427, expiry date: 13-APR-2017 (dose and strength unspecified). No concomitant medications were reported. No adverse effects were reported. The high temperature and low temperature were 4.9 and -4.7 respectively. There were no product quality complaints (PQC) involved. No additional information was provided. This is one of several reports from the same reporter. Additional information has been requested.
pt recv vax 15APR97 & 25APR97 pt devel a false rash which was chickenpox-like & consisted of 5 lesions;
no adverse event; received PROQUAD/that experienced a temperature excursion; This spontaneous report was received from a registered nurse referring to unknown patients of unknown age and gender. Pertinent medical history, concomitant medications and drug reactions/allergies were not reported.  On 11-JUL-2022, following vaccines were administered after temperature excursion to 10.8 degree Celsius for 2 hours 27 minutes (product storage error). Names of vaccines involved: measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) (rHA) (lot # U011995, expiration date: 15-APR-2023, lot # U009511 expiration date: 25-MAR-2023, lot# U014656 expiration date: 07-MAY-2023, lot # U022318, expiration date: 15-JUL-2023, lot # T025930, expiration date: 30-JUL-2022, lot # U029619, expiration date: 22-SEP-2023) for prophylaxis (strength, dose and route of administration were not provided), measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) (rHA) (lot #U029319, expiration date: 19-MAR-2023, lot# U024296 expiration date 21-SEP-2023, lot# U039723 expiration date: 15-DEC-2023, lot# U015679 expiration 18-AMY-2023), varicella virus vaccine live (oka/merck) (VARIVAX) (lot #U010396, expiration date: 01-APR-2023, lot# U039723 expiration date: 15-DEC-2023, lot# U015679 expiration date: 18-MAY-2023, U024296 is an invalid lot number for varicella virus vaccine live (oka/merck) (VARIVAX) expiration date reported as 21-SEP-2023) for prophylaxis (all vaccines strength, dose, anatomical location and route of administration were not provided). The reported was unsure how many administrations occurred and did not have individual patient information. No additional adverse event was reported (no adverse event).  This case is non-valid due to the number of patients was unspecified and lack of patients' identifiers.  Follow-up information was received from a registered nurse on 09-AUG-2022. This case was previously considered non-valid but per follow-up it was determined to be valid (there were only 3 patients who receive the vaccines). This spontaneous report refers to a 4 year old male patient. The patient's pertinent medical history, concomitant medications and drug reactions/allergies were not reported. On 14-JUL-2022, the patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (rHA)(PROQUAD) lot # W004027, expiration date 02-AUG-2023, for prophylaxis (dose and route of administration was not provided) that experienced a temperature excursion. No adverse event was reported.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2207USA005428: US-009507513-2208USA004874: